FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Immunology Drugs in Phase III Clinical Development in FRANCE

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Viaskin peanut

            Therapeutic Area: Immunology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 16, 2020

            Details:

            FDA has informed the Company that during its ongoing review of the Biologics License Application for Viaskin™ Peanut and has identified questions regarding efficacy of patch-site adhesion.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Viaskin peanut

            Therapeutic Area: Immunology

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 08, 2020

            Details:

            These studies have been instrumental in highlighting CRV431's therapeutic strengths and have helped guideHepion Pharmaceutical'scurrent planning of NASH clinical trials.